KR20100031838A - Composition containing extract of soybean leaves for prevention, delay or treatment of diabetes - Google Patents

Abstract

PURPOSE: A composition for preventing, delaying or treating diabetes is provided to use in therapeutic agent, medicinal herb formulation, beverage and health food using soybean leaf extract. CONSTITUTION: A pharmaceutical composition for preventing, delaying, or treating diabetes contains soybean leaf extract as an active ingredient. The extract is isolated using water, alcohol, or mixture thereof. The alcohol is C1-C4 low alcohol. The low alcohol is ethanol or methanole. The pharmaceutical composition additionally contains chiroinositol or genistein. A hypoglycemic agent contains soybean leaf extract as an active ingredient.

Description

Composition containing extract of soybean leaves for prevention, delay or treatment of diabetes}

The present invention relates to a composition for preventing, delaying or treating diabetes comprising soybean leaf extract as an active ingredient.

According to the American Diabetes Statistical Association, 1) fasting blood glucose is 140 mg / dl or more, 2) 75 g of glucose is orally administered, and then blood glucose is measured at 30 minute intervals, at least 200 mg / dl for 2 hours, 30 If any one of minutes, 60 minutes, and 90 minutes is 200 mg / dl or more, 3) Glucose Intolerance is diagnosed as diabetes. At present, the prevalence of diabetes in our country is about 10% of the total population suffer from diabetes and hyperglycemia, which is about 10 times more than 20 years ago.

Diabetes, a chronic metabolic disease, causes insufficient glucose to be supplied to tissue cells through the blood, resulting in the presence of many sugars in the blood, causing abnormalities in lipid metabolism, leading to complications such as blood-related diseases. (Strachan WJ & Deary IJ, Diabetes Care 20: 438-445, 1997). Insulin deficiency or inefficient use of glucose in muscle and adipose tissue cells, while increasing the amount of glucose in the blood, leads to two abnormal conditions. When cells lack energy, glucose, they break down fats and use them as energy sources, which leads to weight loss, and chronic diseases, including eye, kidney, neuropathy and cardiovascular disease, and even coma and death. . Symptoms of diabetes vary, but the most common symptom is polyuria, polyps, and high blood sugar levels cause frequent urination by osmotic pressure to excrete glucose and large amounts of water, resulting in severe thirst. You will drink a lot of water and feel hungry and eat a lot of food. In addition, diabetes is a very widespread disease of human tissue, which is chronic skin disease (boil, itching), peripheral nerve disorders (muscle palsy), weak vision, irritability, weight loss, diabetic ketoacidosis, cellular dysfunction ( Cell damage), retinal disease, neuropathy, kidney disease and atherosclerosis. This diabetes is a long time without any symptoms, so it is left to neglect, as a result of the complications will cause fatal damage to the human body. Therefore, it is necessary to reduce the normal blood sugar at the earliest time.

Diabetes mellitus includes insulin-dependent diabetes and insulin-independent diabetes, which differ not only in the timing and nature of the disease, but also in the severity of the disease and how to treat it. Insulin-dependent diabetes requires absolute insulin secretion, requiring repeated, continuous insulin injections. In addition, oral hypoglycemic agents that control blood sugar are used to treat insulin-independent diabetes.Sulfonylureas promote insulin secretion but cause side effects and hypoglycemia in the blood, gastrointestinal tract, cardiovascular system, kidney and skin. Biguanides strains also inhibit glucose production in the liver but have side effects on the gastrointestinal tract. In addition, alpha-glucosidase inhibitors have side effects such as bloating and diarrhea and the possibility of damage to liver tissue. In addition, in the case of non-dependent diabetes patients, diabetes through diet therapy and exercise therapy can lead to normal life without causing complications for decades, the importance of diet therapy is emphasized.

Various medicines and natural foods have been developed to treat and prevent such diabetes. As the medicine, oral hypoglycemic agents, insulin agents, and complications are used, but there are many examples of side effects such as hypoglycemia, allergies, hyperlipidemia, and polyuria. In addition to economic growth, the number of diabetic patients is increasing regardless of age and sex due to changes in eating habits, and there is much interest in researches on the development of food materials that can prevent diabetes and anticipate the treatment effect by controlling blood sugar. In 2002, the size of the domestic health supplement food market reached KRW 135 billion, showing a continuous increase of more than 10% annually. Among them, the sales of blood sugar-related products amounted to 4 billion won in 1997, which is continuously increasing.

Beans are a year-old herb belonging to the legume family, and in the private sector, soy sauce is used to treat food poisoning caused by fish, and to feed soybeans to the first aid for the sounding caused by the stroke. If you drink it is effective. In oriental medicine, the seeds are called soybean or black soybean and have the effects of blood, diarrhea, wind, detoxification, diuresis, obedience, sakha, jaundice, and tonic. The fermented soybeans obtained by steaming and fermenting black soybeans were always or freshwater, and were used for the effects of fever, sweating, dryness, health, nourishment, and heat transfer. , Female Press, 356).

Soybeans are not only rich in protein and lipids, but also contain a large amount of bioactive substances that are involved in physiological control, making them an important part of our diet (Kwon TW, Korea). soybean Digest 17 (1): 1-4, 2000). There is a lot of research on the physiological activity of soybeans, and low incidence of coronary heart disease, breast cancer, prostate cancer and colon cancer in high soybean intake areas, and related to prevention of adult diseases such as osteoporosis, diabetes, anticholesterolemia, and suppressing arteriosclerosis. (Messina MMV, J Ren) Nutr 10 (2): 63-68, 2000; Barnes S et al . , Korea Soybean Digest 15 (2): 81-93, 1998). As described above, a lot of research on soybeans, but there is little research on soybean leaves.

Soybean leaves are called soybean leaves or gwak and healed in forests and societies. They make young herbs and eat them, and they are used for ssam, kimchi and pickles. In particular, the soybean leaves are known as foods commonly used in the Gyeongsang-do area in the form of soybean leaf chanch and soybean kimchi. It can be eaten by picking soft young soybean leaves in summer and using water kimchi, or by cutting yellow deciduous soybean leaves in autumn and seasoning with salted fish. At this time, the physiological activity of blue bean leaf and deciduous yellow bean leaf is considered to be different. Soybean leaves were obtained from sojagol; Keen NT et. al . , Phytochemistry , 11: 1031-1039, 1972) and flavonoid compounds (Park Sung-jong, Master's Thesis, Sunchon National University, 2002). Among the flavonoid compounds, especially apigenin, a camphorol glycoside, afrormosin glycoside, and isoflavone components (pinitol, chiroinositol, genistein, daidzein), etc. are contained. Keung et al . , Chemicobiological Interactions Interactions , 130-132: 919-930, 2000), reducing blood alcohol levels (Xie CI et al . , Alcoholism, Clinical and Experimentalal Research 18: 1443-1447, 1994), prevent bone loss (Ishida H et al . , Biol Pharm Bull 21: 62-66, 1998), MAO inhibitory activity (Keung WM & Vallee BL, Proc . Natl . Acad . Sci . USA, 95: 2195-2203, 1998), benign prostatic hyperplasia and prostate cancer inhibitory activity (Geller J et. al . , The prostate 34: 75-79, 1998), B16 melanoma inhibitory activity (Record IR et al . , Int J Cancer 72: 860-864, 1997), antimutagenic activity (Miyazawa M et. al . , J Agric Food Chem , 47: 1346-1349, 1997), antioxidant, antidiuretic (Vedavanam K et al . , Phytotherapy Research 13: 601-608, 1999), lipid peroxidation inhibitory action (Toda S & Shirataki Y, Phytotherapy Research 13: 163-165, 1999).

Until now, a variety of animal models have been developed and used mainly in studies related to the pathogenesis, prevention and treatment of various adult diseases such as obesity and diabetes, from animals such as pigs, sheep and dogs to animals including rodents such as rats and mice. Research and interest is also increasing (Spiegelaman BM & Flier JS, Cell 87: 377-389, 1996; Chua S & Leibel RL, Diebetes). Rev 5: 2-7, 1997; Carey GB, Med Sci Sports Exerc 29 (11): 1437-1443, 1997; York DA & Hansen B, Animal models of obesity. In Handbook of obesity (Bray, GA, ed), pp. 191-221, 1998; Marcel Dekker et al ., Endocrinology 145 (6): 2666-2679, 2004). In general, model animals express symptoms specifically according to their genetic characteristics. The characteristics of the model animals that are currently used are mainly db / db and spiny mice characterized by hyperglycemia accompanied by obesity, ketoacidosis and high insulin secretion, and ob / ob, yellow, and NZO mice have high obesity and hyperinsulinemia. And insulin resistance, but the high frequency of hyperglycemia is known to be low.

Accordingly, the present inventors have confirmed that the extract of the present invention can be usefully used for preventing, delaying or treating diabetes by extracting soybean leaves from the db / db mouse in the blood glucose lowering effect.

An object of the present invention to provide a pharmaceutical composition for preventing, delaying or treating diabetes containing soybean leaf extract as an active ingredient.

Another object of the present invention is to provide a hypoglycemic agent containing soybean leaf extract as an active ingredient.

Another object of the present invention to provide a functional food for preventing, delaying or improving diabetes containing soybean leaf extract as an active ingredient.

An object of the present invention is to provide a method for delaying and treating diabetes in a diabetic patient using the pharmaceutical composition for preventing, delaying or treating diabetes or a hypoglycemic agent.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing, delaying or treating diabetes containing soybean leaf extract as an active ingredient.

The present invention also provides a hypoglycemic agent containing soybean leaf extract as an active ingredient.

The present invention also provides a functional food for preventing, delaying or improving diabetes containing soybean leaf extract as an active ingredient.

In addition, the present invention provides a method for delaying and treating diabetes comprising administering the pharmaceutical composition for preventing, delaying or treating diabetes or a hypoglycemic agent to a diabetic patient.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for preventing, delaying or treating diabetes containing soybean leaf extract as an active ingredient.

The bean leaf extract is

1) extracting the dried soybean leaves into powder and then adding an extraction solvent;

2) filtering the extract of step 1); And

3) It is preferably prepared by a manufacturing method comprising the step of concentrating the extract of step 2) under reduced pressure, but not limited to the above method.

The soybean leaves can be used without limitation, such as harvested, cultured or commercially available, in a preferred embodiment it is preferable to use the dried after washing with water to remove foreign substances and salts.

The bean leaf extract may be prepared by a conventional extraction method in the art, such as ultrasonic extraction, filtration and reflux extraction. Preferably, the bean leaf dried may be an extract extracted with water, a lower alcohol of C ₁ ~ C ₄ or a mixed solvent thereof, more preferably may be an extract extracted with a lower alcohol of C ₁ ~ C ₄ , most preferably May be an extract extracted with ethanol or methanol. In a preferred embodiment, the dried soybean leaf may be ground to an appropriate size, put in an extraction container, ethanol is extracted using an ultrasonic wave, and filtered with a filter paper to obtain an ethanol extract. At this time, the volume of the ethanol solvent is preferably 5 to 15 times the volume of the ground sample. The extraction time is preferably 1 to 5 days, most preferably 3 days. Thereafter, a method such as concentration or lyophilization may be further roughened.

In an embodiment of the present invention, the soybean leaf extract prepared by the above method showed a blood sugar lowering effect of 50% or more in the diabetic model male db / db mouse. In addition, it is apparent that soybean leaves have been edible since ancient times and are not toxic to their extracts.

In view of this, the soybean leaf extract of the present invention has excellent blood sugar lowering effect and is determined to be very safe, and thus may be very useful for pharmaceutical compositions for preventing, delaying or treating diabetes.

The present invention contains 0.1 to 50% by weight of the soybean leaf extract of the present invention based on the total weight of the pharmaceutical composition as an active ingredient, and may include a pharmaceutically acceptable carrier, excipient or diluent. Dosage forms of the pharmaceutical compositions of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection. The salt is not particularly limited as long as it is pharmaceutically acceptable, and for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, Methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid, etc. can be used.

The pharmaceutical composition of the present invention may be in various oral or parenteral formulations. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The subject to which the pharmaceutical composition of the present invention can be applied is a vertebrate, preferably a mammal, more preferably an experimental animal such as a rat, mouse, rabbit, guinea pig, hamster, dog, cat, and most preferably Are protozoan animals such as chimpanzees and gorillas.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and when parenteral administration, it is preferable to select an external skin or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injection method. Most preferably for oral administration.

The dosage of the pharmaceutical composition of the present invention varies depending on the weight, age, sex, health condition, diet, time of administration, method of administration, excretion rate and severity of the disease of the patient, the daily dosage of soybean leaf extract 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, based on the amount, can be administered 1 to 6 times per day.

The pharmaceutical composition of the present invention may further contain one or more active ingredients exhibiting the same or similar function, and may further comprise chiroinositol or genistein, which is known to exhibit a hypoglycemic effect.

The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.

The present invention also provides a hypoglycemic agent containing soybean leaf extract as an active ingredient.

In an embodiment of the present invention, the soybean leaf extract showed a blood glucose lowering effect of 50% or more in the diabetic male db / db mice. Thus, the soybean leaf extract of the present invention is excellent in blood sugar lowering effect, can be very useful as a hypoglycemic agent.

The hypoglycemic agent of the present invention may further contain one or more active ingredients exhibiting the same or similar functions, and may further include chiroinositol or genistein, which are known to exhibit hypoglycemic effects.

The present invention also provides a functional food for preventing, delaying or improving diabetes containing soybean leaf extract as an active ingredient.

In an embodiment of the present invention, the soybean leaf extract prepared by the above method showed a blood sugar lowering effect of 50% or more in the diabetic model male db / db mouse. In addition, it is apparent that soybean leaves have been edible since ancient times and are not toxic to their extracts. In view of this, the soybean leaf extract of the present invention is excellent in blood sugar lowering effect, and is determined to be very safe, it can be very useful for the functional food for preventing, delaying or improving diabetes.

The functional food according to the present invention may be, for example, various functional foods such as chewing gum, caramel products, candy, ice cream, confectionery, beverage products such as soft drinks, mineral water, alcoholic drinks, vitamins and minerals, and the like. Can be.

The soybean leaf extract of the present invention may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The blending amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or hygiene). Generally, in the preparation of food or beverage, the soybean leaf extract of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less with respect to the raw material. However, in the case of long-term intake for health and hygiene or health control purposes, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.

The functional food of the present invention may contain various flavors, natural carbohydrates, and the like as additional ingredients. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is preferably selected in the range of 0.01 to 0.04 parts by weight, preferably about 0.02 to 0.03 parts by weight, per 100 parts by weight of the health food of the present invention.

In addition to the above, the functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols. And carbonation agents used in carbonated beverages. In addition, the functional food of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. Although the ratio of such an additive is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.

In addition, the present invention provides a method for delaying and treating diabetes comprising administering the pharmaceutical composition or hypoglycemic agent for preventing, delaying or treating diabetes to a diabetic patient.

In an embodiment of the present invention, the soybean leaf extract prepared by the above method showed a blood sugar lowering effect of 50% or more in the diabetic model male db / db mouse. In addition, it is apparent that soybean leaves have been edible since ancient times and are not toxic to their extracts. In view of this, the soybean leaf extract of the present invention is excellent in blood sugar lowering effect, and determined to be very safe, it can be very useful for delaying and treating diabetes.

The pharmaceutical composition or the method of administering the hypoglycemic agent of the present invention is not particularly limited, but may be parenterally administered (for example, intravenously, subcutaneously, intraperitoneally or topically) or orally according to a desired method. Oral administration is preferred.

In addition, the dosage of the pharmaceutical composition or the hypoglycemic agent of the present invention to the human body may vary depending on the age, weight, sex, dosage form, health condition and degree of disease of the patient, and is based on an adult patient who weighs 70 kg. When used, it is generally 0.1 to 1,000 mg / day, preferably 1 to 500 mg / day, and the daily dose of the pharmaceutical composition or hypoglycemic agent per unit dosage form or 1/2, 1/3 or 1 / A dose of 4 may be contained, and may be dividedly administered 1 to 6 times a day at regular intervals according to the judgment of a doctor or a pharmacist.

Since the soybean leaf extract of the present invention exhibits a hypoglycemic effect, it may be usefully used for the treatment, herbal preparations, health supplements and drinks for the prevention, delay or treatment of diabetes.

Hereinafter, the present invention will be described in detail by Examples, Experimental Examples and Preparation Examples.

However, the following Examples, Experimental Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples.

< Example  1> Preparation of Soybean Leaf Water Extract

Soybean leaves purchased from the National Agricultural Cooperative Federation were washed, dried completely using a dryer, and finely chopped.

The finely chopped soybean leaves were immersed in 10 times of water and extracted with hot water for 3 days. The extract was cooled, and the solvent of the supernatant obtained after filtration was evaporated in vacuo to concentrate the extract. The yield was 74.2% (w / w).

< Example  2> Preparation of Soybean Leaf Ethanol Extract

Finely chopped soybean leaves as in Example 1 was immersed in 10% of 100% ethanol (HPLC grade) and extracted using a sonicator (Branson Ultrasonics corporation, USA) for 3 days at room temperature. After the filtration process, the solvent of the obtained supernatant was evaporated in vacuo to concentrate the extract. The yield was 79.5% (w / w).

< Example  3> Preparation of Soybean Leaf Methanol Extract

The extract was obtained by the method of Example 2 using 100% methanol (HPLC grade). The yield was 83.76% (w / w).

< Experimental Example  1> Check the hypoglycemic effect

Four-week-old Formulation Diabetes Model Male db / db mice (Orient Bio, Korea) were divided into two groups and 1% soybean leaf water, ethanol and methanol extracts were added to AIN-93 diet normal diet (Table 1) and drinking water. One diet was taken free diet for six weeks. Animals fasted 12 hours at 6 weeks of dietary ingestion were sacrificed by cardiac sampling to collect blood. Plasma was separated from blood and blood glucose was measured by a glucometer.

AIN-93 diet normal dietary composition (%) ingredient content Casein 14.0 L-cysteine 0.18 Corn starch 46.6 Hojeong Corn Starch 15.5 Sugar 10.0 fibrin 5.0 Soybean oil 4.0 AIN-93 synthetic mineral 3.5 AIN-93 Multivitamin 1.0 Choline Hydrogen Tartrate 0.25 Tertiarybutylhydroquinone (mg) 0.8 lard 0

As a result, as shown in Figure 1 showed a blood sugar lowering effect of more than 50% in the experimental group to which the soybean leaf extract was added as compared to the control.

< Production Example  1> Preparation of Pharmaceutical Formulations

1. Preparation of powder

Bean ethanol extract 2 g of the present invention

1 g lactose

The above components were mixed and packed in airtight bags to prepare powders.

2. Preparation of Tablets

Bean ethanol extract 100 mg of the present invention

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. Preparation of Capsule

Bean ethanol extract 100 mg of the present invention

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

4. Manufacture of rings

1 g soybean ethanol extract of the present invention

Lactose 1.5 g

Glycerin 1 g

0.5 g of xylitol

After mixing the above components, it was prepared to be 4 g per ring in a conventional manner.

5. Manufacture of granules

Bean ethanol extract 150 mg of the present invention

Soybean Extract 50mg

Glucose 200 mg

600 mg of starch

After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules, which were then filled into fabrics.

Preparation Example 2 Preparation of Food

Foods containing soybean leaf ethanol extract of the present invention was prepared as follows.

<2-1> Preparation of Cooking Seasoning

Soybean leaf ethanol extract of the present invention 20 to 95 parts by weight to prepare a cooking seasoning for health promotion.

<2-2> Preparation of Flour Food

0.5 to 5.0 parts by weight of the soybean leaf ethanol extract of the present invention was added to flour, and bread, cake, cookies, crackers and noodles were prepared using the mixture to prepare foods for health promotion.

<2-3> dairy products ( dairy products Manufacturing

5-10 parts by weight of the soybean leaf ethanol extract of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

<2-4> Linear  Produce

Brown rice, barley, glutinous rice, and yulmu were alphanated by a known method to distribute the dried ones, and then prepared into a powder having a particle size of 60 mesh.

Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh.

The grains, seeds and the hot water extract of the present invention or the dry powder of the hot water extract and its polysaccharide fractions were prepared by blending in the following ratio.

Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley),

Seeds (7 parts by weight perilla, 8 parts by weight black beans, 7 parts by weight black sesame seeds),

Soybean leaf ethanol extract of the present invention (3 parts by weight),

Ganoderma lucidum (0.5 parts by weight),

Foxglove (0.5 part by weight)

< Production Example  3> Manufacture of beverage

Bean ethanol extract 1000 mg of the present invention

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components according to the conventional healthy beverage manufacturing method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored Used to prepare beverage compositions of the invention.

Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and intended use.

1 is a diagram showing the hypoglycemic effect of the ethanol extract of soybean leaves of the present invention.

Claims (11)

A pharmaceutical composition for preventing, delaying or treating diabetes containing soybean leaf extract as an active ingredient. The pharmaceutical composition of claim 1, wherein the extract is extracted with water, alcohol or a mixture thereof. The pharmaceutical composition of claim 2, wherein the alcohol is a C ₁ to C ₄ lower alcohol. 4. The pharmaceutical composition of claim 3, wherein the lower alcohol is ethanol or methanol. The pharmaceutical composition according to claim 4, wherein the lower alcohol is ethanol. The pharmaceutical composition according to claim 1, wherein the soybean leaf extract exhibits a hypoglycemic effect. The pharmaceutical composition of claim 1, further comprising chiroinositol or genistein. Blood sugar lowering agent containing soybean leaf extract as an active ingredient. 9. The hypoglycemic agent according to claim 8, further comprising chiroinositol or genistein. Functional food for preventing, delaying or improving diabetes containing soybean leaf extract as an active ingredient. A method for delaying and treating diabetes, comprising administering the pharmaceutical composition for preventing, delaying or treating diabetes of claim 1 or the hypoglycemic agent of claim 8.

Images